ArticleJournal of clinical laboratory analysis2019
The association of five preoperative serum tumor markers and pathological features in patients with breast cancer.
Article in Journal of clinical laboratory analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review.Exploration of targeted anti-tumor therapy · 2025Pooled it
- Identification of lncRNAs in Breast Cancer Through Bioinformatics Analysis: Implications for Pathogenesis and Prognostic Significance.Cancer medicine · 2026Article
- Relationship between clinical characteristics and serum tumor markers in connective tissue disease with interstitial lung disease as the initial manifestation.Archives of medical science : AMS · 2026Article
- Simultaneous detection of membrane protein and mRNA at single extracellular vesicle level by droplet microfluidics for cancer diagnosis.Journal of advanced research · 2025Article
- Low-Invasive Biomarkers of Canine Mammary Tumours.Veterinary medicine and science · 2025Review
- Article
- Personalized prediction of breast cancer candidates for Anti-HER2 therapy usingFrontiers in oncology · 2025Article
- The Effects of Preoperative Serum Carcinoembryonic Antigen, Cancer Antigen 15-3 and Cancer Antigen 125 on the Prognosis of Breast Cancer Patients With Different Molecular Subtypes.Journal of clinical medicine research · 2024Article
- Review
- Clinical Value on Combined Detection of Serum CA724, DKK1, and TK1 in Diagnosis of Gastric Cancer.Journal of oncology · 2022Article
- Expression levels and clinical values of miR-92b-3p in breast cancer.World journal of surgical oncology · 2021Article
- The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer.Cureus · 2021Article
- Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients.Scientific reports · 2021Article
- Article
- Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.Disease markers · 2021Article
- Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer.Frontiers in oncology · 2021Article
- How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects.International journal of molecular sciences · 2020Review
- Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.Journal of clinical laboratory analysis · 2020Article
- The association of five preoperative serum tumor markers and pathological features in patients with breast cancer.Journal of clinical laboratory analysis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe utility of frequently used serum tumor markers in breast cancer remains controversial. The study aimed to investigate the role of preoperative carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 153 (CA153), cancer antigen 724 (CA724), and ferritin (FER) in the management of breast cancer and their relationships with pathological features.
methodsA total of 804 patients with breast mass who underwent breast surgery and 305 healthy volunteers were enrolled. Preoperative serum levels of CEA, CA125, CA153, CA724, and FER were measured. And the pathological features of all the patients were recorded. The association of preoperative serum tumor markers and pathological features was analyzed.
resultsAmong the 804 patients, 355 were identified as malignant cases and 449 as benign cases. CEA, CA153, and FER of patients with breast cancer were higher than those of healthy volunteer group and patients with benign breast diseases. The area under curve (AUC) of CEA, CA153, and FER for distinguishing patients with breast cancer and subjects with non-breast cancer was 0.688 (95% CI: 0.656-0.721), 0.609 (95% CI: 0.574-0.645), and 0.623 (95% CI: 0.586-0.660), respectively. CA153 correlated with tumor size, node status, and TNM stage, whereas CA125 with node status. No statistic differences of the five markers were observed among the four molecular subtypes.
conclusionPreoperative levels of CEA, CA153, and FER exhibit low diagnostic accuracy for breast cancer (stage I-III). CA153 correlates with tumor burden, suggesting its prognostic value. The five serum markers do not correlate with molecular subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.